Literature DB >> 20813778

Composite MRI scores improve correlation with EDSS in multiple sclerosis.

A H Poonawalla1, S Datta, V Juneja, F Nelson, J S Wolinsky, G Cutter, P A Narayana.   

Abstract

BACKGROUND: Quantitative measures derived from magnetic resonance imaging (MRI) have been widely investigated as non-invasive biomarkers in multiple sclerosis (MS). However, the correlation of single measures with Expanded Disability Status Scale (EDSS) is poor, especially for studies with large population samples.
OBJECTIVE: To explore the correlation of MRI-derived measures with EDSS through composite MRI scores.
METHODS: Magnetic resonance images of 126 patients with relapsing-remitting MS were segmented into white and gray matter, cerebrospinal fluid, T2-hyperintense lesions, gadolinium contrast-enhancing lesions, T1-hypointense lesions ('black holes': BH). The volumes and average T2 values for each of these tissues and lesions were calculated and converted to a z-score (in units of standard deviation from the mean). These z-scores were combined to construct composite z-scores, and evaluated against individual z-scores for correlation with EDSS.
RESULTS: Composite scores including relaxation times of different tissues and/or volumetric measures generally correlated more strongly with EDSS than individual measures. The maximum observed correlation of a composite with EDSS was r = 0.344 (p < 0.0001), which is an improvement over the highest-performing single MRI measure (BH; r = 0.298, p < 0.001).
CONCLUSION: Z-transformation permits construction of composite scores including volumetric and T2-relaxation measures. Inclusion of multiple MRI measures in the composite can provide a broader characterization of the disease process, resulting in more robust correlations with EDSS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20813778      PMCID: PMC2935291          DOI: 10.1177/1352458510374892

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  51 in total

1.  MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients.

Authors:  Maria Pia Sormani; Paolo Bruzzi; Giancarlo Comi; Massimo Filippi
Journal:  Neurology       Date:  2002-02-12       Impact factor: 9.910

2.  Concurrent validity of the MS Functional Composite using MRI as a biological disease marker.

Authors:  N F Kalkers; L Bergers; V de Groot; R H Lazeron; M A van Walderveen; B M Uitdehaag; C H Polman; F Barkhof
Journal:  Neurology       Date:  2001-01-23       Impact factor: 9.910

3.  United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.

Authors:  J S Wolinsky; P A Narayana; K P Johnson
Journal:  Mult Scler       Date:  2001-02       Impact factor: 6.312

4.  Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses.

Authors:  J Petkau; S C Reingold; U Held; G R Cutter; T R Fleming; M D Hughes; D H Miller; H F McFarland; J S Wolinsky
Journal:  Mult Scler       Date:  2008-06-05       Impact factor: 6.312

5.  Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators.

Authors:  J S Wolinsky; P A Narayana; J H Noseworthy; F D Lublin; J N Whitaker; A Linde; P Gjörstrup; H C Sullivan
Journal:  Neurology       Date:  2000-05-09       Impact factor: 9.910

6.  Optimizing the association between disability and biological markers in MS.

Authors:  N F Kalkers; E Bergers; J A Castelijns; M A van Walderveen; J C Bot; H J Adèr; C H Polman; F Barkhof
Journal:  Neurology       Date:  2001-10-09       Impact factor: 9.910

7.  MRI as an outcome in multiple sclerosis clinical trials.

Authors:  M Daumer; A Neuhaus; S Morrissey; R Hintzen; G C Ebers
Journal:  Neurology       Date:  2008-12-10       Impact factor: 9.910

8.  MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study.

Authors:  J Bellmann-Strobl; H Stiepani; J Wuerfel; G Bohner; F Paul; C Warmuth; O Aktas; K P Wandinger; F Zipp; R Klingebiel
Journal:  Eur Radiol       Date:  2009-03-24       Impact factor: 5.315

Review 9.  Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis.

Authors:  D H Miller; A J Thompson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

10.  Variations in T1 and T2 relaxation times of normal appearing white matter and lesions in multiple sclerosis.

Authors:  V L Stevenson; G J Parker; G J Barker; K Birnie; P S Tofts; D H Miller; A J Thompson
Journal:  J Neurol Sci       Date:  2000-09-15       Impact factor: 3.181

View more
  18 in total

1.  Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study.

Authors:  Jennifer Moodie; Brian C Healy; Guy J Buckle; Susan A Gauthier; Bonnie I Glanz; Ashish Arora; Antonia Ceccarelli; Shahamat Tauhid; Xue-Mei Han; Arun Venkataraman; Tanuja Chitnis; Samia J Khoury; Charles R G Guttmann; Howard L Weiner; Mohit Neema; Rohit Bakshi
Journal:  J Neurol Sci       Date:  2011-12-28       Impact factor: 3.181

Review 2.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

3.  Composite biomarkers for assessing Duchenne muscular dystrophy: an initial assessment.

Authors:  Irina Shklyar; Amy Pasternak; Kush Kapur; Basil T Darras; Seward B Rutkove
Journal:  Pediatr Neurol       Date:  2014-10-07       Impact factor: 3.372

4.  The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: Design and baseline characteristics.

Authors:  Jw Lindsey; Tf Scott; Sg Lynch; Ss Cofield; F Nelson; R Conwit; T Gustafson; Gr Cutter; Js Wolinsky; Fd Lublin
Journal:  Mult Scler Relat Disord       Date:  2012-02-23       Impact factor: 4.339

5.  Inversion Recovery Ultrashort TE MR Imaging of Myelin is Significantly Correlated with Disability in Patients with Multiple Sclerosis.

Authors:  H Jang; Y-J Ma; E Y Chang; S Fazeli; R R Lee; A F Lombardi; G M Bydder; J Corey-Bloom; J Du
Journal:  AJNR Am J Neuroradiol       Date:  2021-02-18       Impact factor: 3.825

Review 6.  Clinical correlates of grey matter pathology in multiple sclerosis.

Authors:  Dana Horakova; Tomas Kalincik; Jana Blahova Dusankova; Ondrej Dolezal
Journal:  BMC Neurol       Date:  2012-03-07       Impact factor: 2.474

7.  A comprehensive approach to the segmentation of multichannel three-dimensional MR brain images in multiple sclerosis.

Authors:  Sushmita Datta; Ponnada A Narayana
Journal:  Neuroimage Clin       Date:  2013-01-11       Impact factor: 4.881

8.  Microwave & magnetic (M2) proteomics reveals CNS-specific protein expression waves that precede clinical symptoms of experimental autoimmune encephalomyelitis.

Authors:  Itay Raphael; Swetha Mahesula; Anjali Purkar; David Black; Alexis Catala; Jonathon A L Gelfond; Thomas G Forsthuber; William E Haskins
Journal:  Sci Rep       Date:  2014-09-03       Impact factor: 4.379

9.  Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.

Authors:  Shahamat Tauhid; Renxin Chu; Rahul Sasane; Bonnie I Glanz; Mohit Neema; Jennifer R Miller; Gloria Kim; James E Signorovitch; Brian C Healy; Tanuja Chitnis; Howard L Weiner; Rohit Bakshi
Journal:  J Neurol       Date:  2015-07-24       Impact factor: 4.849

10.  Electrophysiologic biomarkers for assessing disease progression and the effect of riluzole in SOD1 G93A ALS mice.

Authors:  Jia Li; Minhee Sung; Seward B Rutkove
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.